H.P. Acthar® Gel (repository corticotropin injection) Reference Bibliography

This bibliography contains verifiable peer-reviewed manuscripts and abstracts on the use of Acthar Gel, as well as publications supported by Mallinckrodt that relate to Acthar directly or indirectly. Human and preclinical studies, health economic and outcomes analyses (HEOR), reports and reviews are included and, where available, links to PubMed are provided.

Updated February 2019

Nephrology


33. Lafayette RA, Root C, Metha K. Adrenocorticotropic hormone (ACTH) for the treatment of primary focal glomerulosclerosis (FSGS) [NKF abstract 140]. Am J Kidney Dis. 2012;59(4);B49


**Nephrology HEOR**


Neurology


112. Molitor RE, Stewart J. Home intravenous administration of adrenocorticotropin hormone in
113. Mytinger JR, Weber A, Heyer GL. The response to ACTH is determined early in the treatment
of infantile spasms [AES abstract 3.144]. *Epilepsy Curr.* 2014;14(suppl 1):360
114. Mytinger JR, Weber A, Heyer GL. The response to ACTH is determined early in the treatment
115. Murray S., Woo A. Clinical experience with repository corticotropin injection in patients with
multiple sclerosis experiencing mood changes with intravenous methylprednisolone: A case
117. Nickerson M, Cofield SS, Tyry T, Salter AR, Cutter GR, Marrie RA. Impact of multiple
sclerosis relapse: The NARCOMS participant perspective. *Mult Scler Relat Disord.*
2015;4(3):234-240. [Link]
118. Pagnotta PA, LaGanke C, Easterling CB. Using Acthar in Lemtrada infusion protocol
[CMSC/ACTRIMS abstract DX53] *Int J MS Care.* 2017;19(suppl 1):31
119. Park JT, Chugani HT. Epileptic spasms in paediatric post-traumatic epilepsy at a tertiary
120. Partikian A, Mitchell WG. Major adverse events associated with treatment of infantile spasms.
*J Child Neurol.* 2007;22(12):1360-1366. [Link]
121. Pauli L, O'Neil R, Ybanez M, Livingston S. Minor motor epilepsy. Treatment with corticotropin
(ACTH) and steroid therapy. *JAMA.* 1960;1408-1412. [Link]
Dwyer M, Zivadinov R, Weinstock-Guttman B, Benedict R. Replication of cognitive relapse
phenomenon in multiple sclerosis in association with gadolinium enhancing lesions
123. Pranzatelli MR, Tate ED, McGee NR, et al. Key role of CXCL13/CXCR5 axis for
[Link]
2010;32(5):e167-e172. [Link]
125. Pranzatelli MR, Tate ED, Crowley JM, Toennies B, Creer M. Neurometabolic effects of ACTH
on free amino compounds in opsonocluon-myoclonus syndrome. *Neuropediatrics.*
2008;39(3):164-171. [Link]
126. Pranzatelli MR, Chun KY, Moxness M, Tate ED, Allison TJ. Cerebrospinal fluid ACTH and
127. Pranzatelli MR, Huang YY, Tate E, et al. Monoaminergic effects of high-dose corticotropin in
[Link]
128. Pranzatelli MR, Allison TJ, Tate ED. Effect of low-dose cyclophosphamide, ACTH, and IVIG
combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective
129. Rao JK, Willis J. Hypothalamic-pituitary-adrenal function in infantile spasms: effects of ACTH
130. Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. Cooperative
study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.
131. Ross AP, Halper J, Harris CJ. Assessing relapses and response to relapse treatment in
[Link]
133. Ryan N, Coryell J, Nickels K, Mytinger J, Knupp K. The national infantile spasms consortium
(NISC): Moving towards standardization of care and improved treatment and outcomes in


Neurology – HEOR


159. Hansen R, Gold L, Schepman P, Niewoehner J, Philbin M. Economic consequences of early versus late use of adrenocorticotropic hormone therapy in infantile spasms [WCI abstract LB10]. Late-brocker abstract presented at World Congress of Inflammation Meeting; August 8-12, 2015; Boston, MA. 2015


### Ophthalmology


### Ophthalmology HEOR


**Pulmonology**


**Pulmonology – HEOR**


Gaylis N, Needell S, Sagliani J. The effect of corticotropin (ACTH 80 units weekly or biweekly) in combination with MTX in newly diagnosed RA patients from a clinical and structural perspective as measured by a CDAI score and osteitis, synovitis, and erosions on MRI [EULAR abstract AB0503]. Ann Rheum Dis. 2015;74(suppl 2):1066-1067


Gillies TM, Crane M, Hinkle C, Wei N. H.P. Acthar® Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic therapies with different modes of action [EULAR abstract AB0502]. Ann Rheum Dis. 2015;74(suppl 2):1066-1066


250. Wu A, June J. Case series: Comparison of repository corticotropin injection (H.P. Acthar Gel) versus glucocorticoids on bone density in SLE patients [ACR abstract 331]. *Arthritis Rheumatol.* 2017;69(supp 10):452

251. Zutshi DW, Friedman M, Ansell BM. Corticotrophin therapy in juvenile chronic polyarthritis (still’s disease) and effect on growth. *Arch Dis Child.* 1971;46(249):584-593. Link

**Rheumatology – HEOR**


15


Abe T, Matsuo K, Tomomura D, et al. A randomized controlled trial of methylprednisolone pulse therapy for exacerbation of multiple sclerosis [AAN abstract P05.02]. *Neurology.* 2012;78(suppl 1):21-P05.02


301. Decker D, Higgins P, Bendele A, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) attenuates established collagen-induced arthritis when used alone or as adjuvant therapy with Etanercept (Enbrel®) [AAI abstract THER5P.902]. J Immunol. 2015;194(suppl 1):139.4-139.4


316. Hogan JJ, Jai R, Gerald BA, Andrew SB, Pietro AC, Maya KR. Treatment of resistant primary focal segmental glomerulosclerosis (FSGS) with adrenocorticotropic hormone (ACTH) gel [ASN abstract SA-PO381]. J Am Soc Nephrol. 2012;23(suppl):725A


318. Jensen MA, Abraham P, Reder AT, Arnason BGW. Co-production of GM-CSF, IL-22, or IL-17F identifies a pathogenic high IL-17A-producing T cell subset from MS patients that is steroid resistant [ANA abstract S151]. Ann Neurology. 2016;80:S53-S54.


322. Kongelbeck SR. Discharge planning for the child with infantile spasms. J Neurosci Nurs. 1990;No. 4:238-244. Link


333. Lisak RP, Nedelkoska L, Benjamins JA. Melanocortin 4 receptors on oligodendrocytes and oligodendrocyte precursors signal ACTH protection from in vitro death induced by mechanisms involved in cell damage in multiple sclerosis.[ECTRIMS abstract P579]. *Mult Scler*. 2015;23(11 suppl 1):273,

334. Lisak R, Nedelkoska L, Benjamins J. ACTH1-39 protection of oligodendrocytes from damage relevant to multiple sclerosis involves both direct and indirect mechanisms. [AAN abstract P2.189]. *Neurology*. 2015;84(14 suppl 1):P2.189


346. Montroy T, Fiechtner JJ. A single-site, investigator initiated, open-label trial of the adrenocorticotropic hormone (ACTH) analogue HP Acthar Gel (repository corticotropin injection) among subjects with moderately to severely active systemic lupus erythematosus (SLE) [EULAR abstract AB0382]. Ann Rheum Dis. 2013;72(suppl 3):904


